Dr Troy Wanandy
National Centre of Excellence Insect Allergy Stream Co-chair
- Senior Specialist Pharmacist in Allergy and Immunology, and Quality Manager, Department of Clinical Immunology and Allergy, Royal Hobart Hospital
- Head of Manufacturing Quality, Jack Jumper Allergy Program, Royal Hobart Hospital
- Research Associate, College of Health and Medicine, University of Tasmania
- Leader of the Jack Jumper Venom Allergy Research Group, University of Tasmania
Dr Troy Wanandy is one of the few hospital pharmacists specialising in clinical immunology and allergy in Australia. He has an extensive background in Hospital Pharmacy, Manufacturing and Quality Assurance of Pharmaceuticals.
As a practicing research pharmacist and Adjunct Researcher at the University of Tasmania, Dr Wanandy’s research interests include understanding allergic disease, particularly insect venom and drug allergies, and clinical pharmaceutics. He leads the Jack Jumper Venom Allergy Research Group at the University of Tasmania, which main objective is to investigate and optimise the delivery of venom immunotherapy as a treatment modality to prevent life-threatening anaphylaxis from insect stings in otherwise healthy people. He is also working on studies that explore physico-chemical and microbiological stability of pharmaceuticals.
Dr Wanandy works at Royal Hobart Hospital as a Senior Specialist Pharmacist for the Department of Clinical Immunology and Allergy. He is a recipient of the Tasmanian Allied Health Award in ‘Putting Research into Practice’ category.
RECENT PUBLICATIONS
Leech-bite induced anaphylaxis with or without Hymenoptera venom sensitization. The Journal of Allergy and Clinical Immunology: In Practice. Jul 2024
Stinging Ant Anaphylaxis: Advances in Diagnosis and Treatment. The Journal of Allergy and Clinical Immunology: In Practice. Jul 2024
The Human Health Impacts of the Red Imported Fire Ant in the Western Pacific Region Context: A Narrative Review. Tropical Medicine and Infectious Disease. Mar 2024
Comparative study of the commonly used protein quantitation assays on different Hymenoptera venoms: A fundamental aspect of Hymenoptera venom proteome analysis. Toxicon. Apr 2024
The development of Jack Jumper ant venom immunotherapy: our 25 years' experience. Internal Medicine Journal. Sept 2023
Verification of the Bühlmann fPELA turbo faecal elastase assay on the Binding Site Optilite benchtop analyser. Annals of Clinical Biochemistry. Oct 2022
Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management. Clinical Reviews in Allergy & Immunology. Jun 2021
Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Peritoneal Dialysis International. Feb 2020
Pyridine levels in ceftazidime – peritoneal dialysis admixtures stored at body temperature. Peritoneal Dialysis International. Jan 2020
Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach. Clinical & Experimental Allergy. Jul 2018
SELECTED STUDIES
KEY RESOURCES
Proudly in partnership with the National Allergy Council and allergy organisations
